Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients
| Autor: | Jaques Montplaisir, Judith Laredo, Sophie Keufer-Le Gall, Pierre Philip, Goeran Hajak, MA Quera-Salva, Christian Guilleminault |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Agonist medicine.medical_specialty medicine.drug_class Polysomnography Citalopram law.invention Double-Blind Method Randomized controlled trial Rating scale law Internal medicine Acetamides mental disorders medicine Humans Hypnotics and Sedatives Escitalopram Agomelatine Pharmacology (medical) Wakefulness Melatonin Morning Depressive Disorder Major business.industry Middle Aged medicine.disease Psychiatry and Mental health Treatment Outcome Major depressive disorder Antidepressant Female Sleep Stages business Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | International Clinical Psychopharmacology. 26:252-262 |
| ISSN: | 0268-1315 |
| DOI: | 10.1097/yic.0b013e328349b117 |
| Popis: | Agomelatine, an MT1/MT2 receptor agonist and 5-HT2C receptor antagonist antidepressant, is known to have beneficial effects on subjective sleep in major depressive disorder patients. This international multicenter, randomized, double-blind study compared the effects of agomelatine (25-50 mg/day) and escitalopram (10-20 mg/day) on sleep polysomnographic parameters in major depressive disorder patients treated up to 24 weeks. A total of 138 outpatients were randomly allocated to agomelatine (n=71) or escitalopram (n=67). Treatment with agomelatine was associated with a reduction in sleep latency from week 2 onward. The difference between treatments was significant on all evaluations. Rapid eye movement latency was increased with escitalopram compared with agomelatine, with significant between-group differences at every visit. Agomelatine preserved the number of sleep cycles, whereas it was decreased with escitalopram with significant between-group differences at every visit. Assessments on visual analogue scales indicated that treatment with agomelatine improved morning condition, and reduced daytime sleepiness compared with escitalopram.17-item Hamilton depression rating scale total score was reduced in both groups, agomelatine was statistically noninferior to escitalopram at 6 weeks. Both treatments were well tolerated. This study showed that the clinical effects of agomelatine on sleep and wake parameters are different from that of escitalopram. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|